■评估用拉坦前列素(LT)0.005%治疗的患者的眼表,这些患者改用拉坦前列汀布诺(LBN)0.024%。
■进行了病例系列的前瞻性和非随机临床研究,包括以前仅接受LT治疗的慢性开角型青光眼患者,经过一段冲洗期,切换到LBN,3个月的随访。评估的主要参数是眼表疾病指数(OSDI)测试。此外,最佳矫正视力(BCVA),眼内压(IOP),眼表的生物显微镜方面,测量眼泪破裂时间,评估荧光素染色(按牛津量表进行分级)和SchirmerI测试。
■共纳入36例患者(72只眼),21名女性(58.3%)和15名男性(41.7%,平均年龄65.6±10.9岁(37-86岁)。初始OSDI评分为17.8±12.1,改善至11.1±10.5(p<0.01)。从生物显微镜评估的数据来看,在牛津量表中观察到从0.6±0.7到0.2±0.8的改善(p:0.01),但在分手时间(BUT)和Schirmer中未观察到统计学上的显着变化。BCVA保持稳定,就像IOP一样,最初为13.4±2.1mmHg,在进行LBN治疗改变后,达到13.1±1.7mmHg。
■处理从LT0.005%变为LBN0.024%后,患者的眼表有所改善,保持对IOP的控制。需要研究LBN治疗的青光眼患者眼表可能的有益机制,可能与一氧化氮有关,提高了。
■接受0.005%LT治疗且改用0.024%LBN的患者眼表症状和体征有所改善,控制IOP。Latanoprostenebunod(LBN)0.024%可能对眼表有益的影响,这应该进一步研究。
■ZanutighV,GalettoL,ValvecchiaF,etal.在从拉坦前列素0.005%切换到拉坦前列素0.024%之后的眼部表面评估。JCurr青光眼Pract2023;17(4):205-209。
UNASSIGNED: To evaluate the ocular surface of patients treated with latanoprost (LT) 0.005% who switched to latanoprostene bunod (LBN) 0.024%.
UNASSIGNED: A prospective and nonrandomized clinical study of a case series was performed, including patients with chronic open-angle glaucoma who were on previous LT-only treatment and, after a washout period, switched to LBN, with a 3-month follow-up. The main parameter to be evaluated was the ocular surface disease index (OSDI) test. In addition, best-corrected visual acuity (BCVA), intraocular pressure (IOP), biomicroscopic aspect of the ocular surface, measuring tear breakup time, fluorescein staining (grading performed on Oxford scale) and Schirmer I test were evaluated.
UNASSIGNED: A total of 36 patients (72 eyes) were included, 21 women (58.3%) and 15 men (41.7%, with a mean age of 65.6 ± 10.9 years (37-86). The initial OSDI score was 17.8 ± 12.1 and improved to 11.1 ± 10.5 (p < 0.01). From the data evaluated at biomicroscopy, an improvement was observed in the Oxford scale from 0.6 ± 0.7 to 0.2 ± 0.8 (p: 0.01), but no statistically significant changes were observed in the break-up time (BUT) and Schirmer. BCVA remained stable, as did IOP, which was initially 13.4 ± 2.1 mm Hg and, after performing the LBN treatment change, went to 13.1 ± 1.7 mm Hg.
UNASSIGNED: After the change of treatment from LT 0.005% to LBN 0.024%, the patients had an improvement in the ocular surface, maintaining control of their IOP. The need to investigate possible beneficial mechanisms on the ocular surface in glaucoma patients treated with LBN, potentially related to nitric oxide, is raised.
UNASSIGNED: Patients treated with LT 0.005% who switched to LBN 0.024% had an improvement in ocular surface symptoms and signs, keeping IOP under control.Latanoprostene bunod (LBN) 0.024% may have beneficial effects on the ocular surface, which should be further studied.
UNASSIGNED: Zanutigh V, Galetto L, Valvecchia F, et al. Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024%. J Curr Glaucoma Pract 2023;17(4):205-209.